Drugs / Moxaverine
Moxaverine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01629680 | Oct 2010 → Mar 2011 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 2 | NCT00569621 | Mar → Jul 2007 | ischemic disease | Medical University of Vienna | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00709449 | May 2008 → Mar 2009 | glaucoma, macular degeneration | Medical University of Vienna | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00709423 Comparator | Mar → May 2007 | retinal disorder | Medical University of Vienna | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Moxaverine | “Drug: Moxaverine” NCT00709423 ↗ |
| Known as | Kollateral forte | “Moxaverine-hydrochloride, coated tablets containing 150 mg moxaverine (Kollateral forte, Ursapharm. Saarbrücken, Germany), dosage: 900 mg, administrated per os in three equal...” NCT01629680 ↗ |
| Known as | Moxaverina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105060 ↗ |
| Known as | Moxaverine-hydrochloride | “Moxaverine-hydrochloride, coated tablets containing 150 mg moxaverine (Kollateral forte, Ursapharm. Saarbrücken, Germany), dosage: 900 mg, administrated per os in three equal...” NCT01629680 ↗ |
| Modality | Small molecule | — CHEMBL2105060 ↗ |
| Route | Intravenous | “intravenous administration” NCT00569621 ↗ |